JP2007508314A - ピロバレロン類縁体及びそれらの治療的使用 - Google Patents

ピロバレロン類縁体及びそれらの治療的使用 Download PDF

Info

Publication number
JP2007508314A
JP2007508314A JP2006534415A JP2006534415A JP2007508314A JP 2007508314 A JP2007508314 A JP 2007508314A JP 2006534415 A JP2006534415 A JP 2006534415A JP 2006534415 A JP2006534415 A JP 2006534415A JP 2007508314 A JP2007508314 A JP 2007508314A
Authority
JP
Japan
Prior art keywords
compound
mammal
substituted
phenyl
pentan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006534415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007508314A5 (https=
Inventor
ケイ マドラス バーサ
シー メルツァー ピーター
バトラー デーヴィッド
Original Assignee
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ
オーガニクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ, オーガニクス インコーポレイテッド filed Critical プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ
Publication of JP2007508314A publication Critical patent/JP2007508314A/ja
Publication of JP2007508314A5 publication Critical patent/JP2007508314A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2006534415A 2003-10-08 2004-10-08 ピロバレロン類縁体及びそれらの治療的使用 Withdrawn JP2007508314A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50988203P 2003-10-08 2003-10-08
PCT/US2004/033349 WO2005034878A2 (en) 2003-10-08 2004-10-08 Pyrovalerone analogs and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
JP2007508314A true JP2007508314A (ja) 2007-04-05
JP2007508314A5 JP2007508314A5 (https=) 2007-11-22

Family

ID=34435034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534415A Withdrawn JP2007508314A (ja) 2003-10-08 2004-10-08 ピロバレロン類縁体及びそれらの治療的使用

Country Status (6)

Country Link
US (1) US20080234498A1 (https=)
EP (1) EP1670755A4 (https=)
JP (1) JP2007508314A (https=)
AU (1) AU2004280256A1 (https=)
CA (1) CA2542077A1 (https=)
WO (1) WO2005034878A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US7846945B2 (en) 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
BR112015014457A2 (pt) 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
GB2530783A (en) * 2014-10-02 2016-04-06 Randox Lab Ltd Improved immunoassay for pyrrolidinophenones
MA55556A (fr) 2019-04-02 2022-02-09 Aligos Therapeutics Inc Composés ciblant prmt5

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314970A (en) * 1967-04-18 Pykrolidino ketones
US3287217A (en) * 1966-11-22 Compositions and methods for stimulat- ing the central nervous system and in- creasing the blood pressure
US2369611A (en) * 1938-12-24 1945-02-13 Scheuing Georg Analgetically effective tetrahydronaphthalene piperidyl derivatives
DE1161274B (de) * 1960-04-07 1964-01-16 Thomae Gmbh Dr K Verfahren zur Herstellung von ª‡-Pyrrolidinoketonen und deren Salzen
CH395998A (de) * 1961-05-05 1965-07-31 Wander Ag Dr A Verfahren zur Herstellung von a-Pyrrolidino-valerophenonen
FR2319332A1 (fr) * 1975-07-28 1977-02-25 Roussel Uclaf Nouveaux derives de l'aminobenzocycloheptene et leurs sels, procede de preparation et application a titre de medicaments desdits produits
HU222726B1 (hu) * 1990-02-06 2003-09-29 Pfizer, Inc., Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények
JPH051033A (ja) * 1991-06-18 1993-01-08 Tanabe Seiyaku Co Ltd ベンゾシクロヘプテン誘導体及びその製法

Also Published As

Publication number Publication date
AU2004280256A1 (en) 2005-04-21
US20080234498A1 (en) 2008-09-25
EP1670755A4 (en) 2007-02-28
WO2005034878A2 (en) 2005-04-21
EP1670755A2 (en) 2006-06-21
WO2005034878A3 (en) 2005-06-30
CA2542077A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
Meltzer et al. 2-Carbomethoxy-3-aryl-8-oxabicyclo [3.2. 1] octanes: potent non-nitrogen inhibitors of monoamine transporters
Vecchietti et al. (1S)-1-(Aminomethyl)-2-(arylacetyl)-1, 2, 3, 4-tetrahydroisoquinoline and heterocycle-condensed tetrahydropyridine derivatives: members of a novel class of very potent. kappa. opioid analgesics
RU2140417C1 (ru) Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения
US20110319416A1 (en) Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
JPH06509069A (ja) シグマレセプターリガンドおよびその用途
JP3731827B2 (ja) アミノメチルインダン、‐ベンゾフラン及び‐ベンゾチオフエン
JP6302929B2 (ja) ヒドロキシ脂肪族置換フェニルアミノアルキルエーテル誘導体
IL292585A (en) 5-ht2a agonists for use in treatment of depression
JP2004502774A (ja) ４−フェニル置換テトラヒドロイソキノリンおよびその使用方法
Tamiz et al. Structure− Activity relationship of N-(Phenylalkyl) cinnamides as novel NR2B subtype-selective NMDA receptor antagonists
US12465578B2 (en) Substituted alpha-ethyl phenylalkylamines
JP2007508314A (ja) ピロバレロン類縁体及びそれらの治療的使用
BR112020024729A2 (pt) compostos de benzenossulfonamida e seu uso como agentes terapêuticos
JP2019512550A (ja) エストロゲン受容体ダウンレギュレーターとしての置換インドール化合物
JP2006519758A (ja) Ｓ−置換ｎ−１−［（ヘテロ）アリール］アルキル−ｎ’−［（ヘテロ）アリール］アルキルイソチオカルバミド、これらの調製のための方法、生理学的に活性なｎ−１−［（ヘテロ）アリール］アルキル−ｎ’−［（ヘテロ）アリール］アルキルイソチオカルバミド、薬学的組成物および処置方法
Oberdorf et al. Thiophene bioisosteres of spirocyclic σ receptor ligands: Relationships between substitution pattern and σ receptor affinity
CN110446495B (zh) 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
WO1995007905A1 (en) Optically active imidazolidinone derivative and process for producing the same
US12428408B2 (en) Fused heterocyclic mescaline derivatives
US7026516B2 (en) Compounds with high monoamine transporter affinity
JP2010529080A (ja) 皮質カテコールアミン作動性神経伝達の調節因子としての新規な二置換フェニルピロリジン
JP3162822B2 (ja) チエノシクロペンタノンオキシムエーテル、製造および組成物
JP2014001142A (ja) シクロアルカン化合物
JP2009536644A (ja) 中枢神経系活動に用いるシクロプロパン
JP4565747B2 (ja) テトラヒドロイソキノリンアルカノール誘導体及びそれを含む薬学的組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071005

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100310